Dual Implant Versus Single Implant Distal End of Femur
Launched by UNIVERSITY OF UTAH · Mar 14, 2022
Trial Information
Current as of September 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The incidence of distal femur fractures in elderly patients continues to increase, most recently having an incidence of 8.7/100,000/year. This trend likely accompanies the aging population and the increased rates of knee arthroplasty. While these fractures are far less common than geriatric hip fractures, distal femur fractures present similar treatment challenges. Elderly distal femur fractures tend to occur in compromised hosts with poor bone mineral density. Similar to geriatric hip fractures, care emphasizes early mobilization to avoid the complications associated recumbency, including ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient age 60 years or greater,
- • Femur fracture distal to the femoral diaphysis,
- • Operative treatment within 72 hours of presenting to the treating hospital,
- • Patient was previously ambulatory,
- • Fracture amendable to either single or dual implant fixation,
- • Informed consent can be obtained from the patient, family member, or power of attorney.
- Exclusion Criteria:
- • Associated major lower extremity fracture,
- • Ongoing infection,
- • History of metabolic bone disease (Paget's, etc),
- • Pathologic fracture,
- • Open fracture,
- • Severe cognitive impairment (Six Item Screener with 3 or more errors),
- • Stage 5 Parkinson's disease,
- • Significant femoral bone loss requiring planned staged bone grafting,
- • Vascular injury.
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Justin Haller, M.D.
Principal Investigator
University of Utah Orthopaedics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials